- Tariffs, tax cuts, energy: What is in Trump's economic plan?
- Amazon wants to be everything to everyone
- Jewish school in Canada hit by gunfire for second time
- With medical report Harris seeks to play health card against Trump
- China-EU EV tariff talks in Brussels end with 'major differences': Beijing
- Buried Nazi past haunts Athens on liberation anniversary
- Harris to release medical report confirming fitness for presidency: campaign
- Nobel prize a timely reminder, Hiroshima locals say
- China offers $325 bn in fiscal stimulus for ailing economy
- Small Quebec company dominates one part of NHL hockey: jerseys
- Boeing to cut 10% of workforce as it sees big Q3 loss
- Want to film in Paris? No sexism allowed
- US, European markets rise as investors weigh rates, earnings
- In Colombia, children trade plastic waste for school supplies
- JPMorgan Chase profits top estimates, bank sees 'resilient' US economy
- Little progress at key meet ahead of COP29 climate summit
- 'Party atmosphere': Skygazers treated to another aurora show
- Kyrgyzstan opens rare probe into glacier destruction
- European Mediterranean states discuss Middle East, migration
- Thunberg leads pro-Palestinian, climate protest in Milan
- Stock markets diverge before China weekend briefing
- EU questions shopping app Temu over illegal products risk
- Han Kang's books sell out in South Korea after Nobel win
- Shanghai markets sink ahead of briefing on mixed day for Asia
- Investors, analysts eye bigger China stimulus at Saturday briefing
- Musk unveils robotaxi, pledges it 'before 2027'
- At least 11 dead in Florida but Hurricane Milton not as bad as feared
- Asian markets mixed after Wall St drop, Shanghai dips before briefing
- Automaker Stellantis says CEO will retire in 2026
- Musk's promised robotaxi unveil delayed
- On US coast, wind power foes embrace 'Save the Whales' argument
- At least 10 dead in Florida after Hurricane Milton spawns tornadoes
- Internet Archive reels from 'catastrophic' cyberattack, data breach
- Wall Street stocks retreat from records on US inflation data
- Israel strikes central Beirut, killing 22
- Solar storm could impact US hurricane recovery efforts: agency
- Delta eyes Election Day travel pullback as profits climb
- Florida battered by hurricane, floods but spared 'worst-case scenario'
- UK's William and Kate in first joint public engagement since cancer treatment
- Over 200 women in legal talks with Harrods over Fayed abuse claims
- A very stiff breeze: BBC says sorry for 20,000 kph wind forecast
- Musk finally unveiling his long-promised robotaxi
- London's Frieze art fair goes potty for ceramics
- US, Europe stocks fall on US inflation data
- US consumer inflation eases to 2.4% in September
- Hurricane Milton tornadoes kill four in Florida amid rescue efforts
- South Korea's Han Kang wins literature Nobel
- Ikea posts fall in annual sales after lowering prices
- Stock markets diverge, oil gains after China rebounds
- World can't 'waste time' trading climate change blame: COP29 hosts
Pfizer profits drop as it adapts to lower Covid-19 revenues
Pfizer reported a drop in first-quarter profits Tuesday on declining Covid-19 vaccine revenues, but said it was on track for a heavy series of product launches later in 2023.
Shares of the pharma giant edged higher as Pfizer Chief Executive Officer Albert Bourla touted an "unprecedented" number of new launches to help offset an ebbing of Covid-19-related sales that have boosted profits in recent years.
These include the migraine drug Zavzpret and the Prevnar pneumonia vaccine for children. Pfizer is also targeting growth in cancer treatments, having announced in March an acquisition of biotech company Seagen for $43 billion.
Bourla said integration planning for Seagen is underway and that the deal is expected to close in late 2023 or early 2024.
Pfizer's profits in the first quarter were $5.5 billion, down 30 percent from the year-ago period.
Revenues fell 29 percent to $18.3 billion following a $10 billion drop from Covid-19 vaccine Comirnaty.
Bourla described 2023 as a "transition year" for its Covid-19 products.
The company expects vaccine utilization to decline in 2023 and 2024, but to see an uptick starting in 2025 "assuming the successful development and approval of various Covid combination vaccines," Bourla said in prepared remarks.
Pfizer has also forecast a 2023 decline in revenues in Paxlovid, its Covid-19 therapeutic. The company attributes the decline this year to earlier purchases by governments to build inventories.
"We then expect that in the years 2024 and beyond the courses sold and used will more closely align," Bourla said, describing Paxlovid as a valuable tool in blocking the virus from progressing to a severe condition in infected patients.
Shares were up 0.8 percent at $39.52 in pre-market trading.
P.Kolisnyk--CPN